Szara, S; Hearst, E; Putney, F. Metabolism and behavioural action of psychotropic tryptamine homologues. Int. J. Neuropharmacol., 1 Nov 1962, 1 (1–3), 111–117. 1.1 MB. https://doi.org/10.1016/0028-3908(62)90015-1
Kalir, A; Szara, S. Synthesis and pharmacological activity of alkylated tryptamines. J. Med. Chem., 1 May 1966, 9 (3), 341–344. 482 kB. https://doi.org/10.1021/jm00321a017
Shulgin, AT. Psychotomimetic agents. In Psychopharmacological Agents; Gordon, M, Ed., Academic Press, New York, ; Vol. 4, pp 59–146. 3.1 MB. #XXXV
Blair, JB; Kurrasch-Orbaugh, D; Marona-Lewicka, D; Cumbay, MG; Watts, VJ; Barker, EL; Nichols, DE. Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. J. Med. Chem., 1 Nov 2000, 43 (24), 4701–4710. 494 kB. https://doi.org/10.1021/jm000339w #1c MS,NMR
Brimblecombe, RW; Pinder, RM. Hallucinogenic agents, Wright-Scientechnica, Bristol, UK, 1 Jan 1975. 46.2 MB.
5-MeO-2-Me-DMT · 5-MeO-TMT · 5-Methoxy-2-methyl-DMT · MMDT
5-MeO-α,N,N-TMT · 5-MeO-α-Me-DMT
5-MeO-7-Me-DMT · 5-Methoxy-7-methyl-DMT
N-Methyl-acetyl-norfentanyl